Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, forecast profit and revenue for calendar 2013 that fell short of analysts' estimates.

The Israel-based company, which posted a higher-than-expected quarterly profit earlier this month on strong U.S. revenue, forecast an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.

Analysts' average forecast is $5.71 per share on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.

Teva expects revenue from its generic drugs of $10.3 billion to $10.7 billion next year, and sales of branded medications of $7.6 billion to $8 billion.

The company expects sales of its drug Copaxone, for multiple sclerosis, to range between $3.7 billion and $3.9 billion.